|
|
|
|
cross-reacting material 197, a specific inhibitor of hb-egf, and its anticancer effects
|
|
|
|
|
|
|
|
نویسنده
|
tanhapour maryam ,golestani abolfazl ,vaisi-raygani asad ,aminian mahdi
|
|
منبع
|
basic and clinical cancer research - 2021 - دوره : 13 - شماره : 1 - صفحه:30 -50
|
|
چکیده
|
Genetic heterogeneity and metastasis remain the most challenging aspects of cancer treatment.recent studies have introduced a mutant of diphtheria toxin,cross-reacting material197 (crm197), as a new promising biological anticancer drug to improve cancer therapy in patients previously resistant to chemotherapy. weak toxicity of crm197accounts forthe stimulation ofcell apoptosis and the antitumor effect. increasing evidence has indicated that the expression of heparin-binding epidermal growth factor-like (hb-egf) growth factorincreases in most cancer cells, and crm197 is its specific inhibitor.this study has focused on the structure, properties, and anticancer activity of crm197.
|
|
کلیدواژه
|
cancer ,cross-reacting materials 197 (crm197) ,diphtheria toxin (dt) ,epidermal growth factor receptor (egfr) ,heparin-binding egf-like growth factor (hb-egf)
|
|
آدرس
|
tehran university of medical sciences, school of medicine, department of clinical biochemistry, iran. kermanshah university of medical sciences, school of medicine, department of clinical biochemistry, iran, tehran university of medical sciences, school of medicine, department of clinical biochemistry, iran, kermanshah university of medical sciences, school of medicine, department of clinical biochemistry, iran, tehran university of medical sciences, school of medicine, department of clinical biochemistry, iran
|
|
پست الکترونیکی
|
amminian@tums.ac.ir
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|